A combination of two drugs could improve outcomes and reduce the need for toxic chemotherapy for B-cell acute lymphoblastic leukemia (B-ALL), the commonest cancer in childhood and one that can be ...

A combination of two drugs could improve outcomes and reduce the need for toxic chemotherapy for B-cell acute lymphoblastic ...

You feel like you have the flu, but you’re not getting better Fever, chills, muscle aches and sleepiness are all classic ...

Discover upcoming breakthroughs in Type 1 Diabetes & B-cell disorder treatments, market growth to $24B by 2031, and key ...

Margrit Wiesendanger, MD, PhD, explores lupus symptoms, diagnosis challenges, and the importance of early detection to prevent inflammation-related damage.

AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on discovery ...

Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded ...

INB-619 precisely targets and eliminates B cells from lupus patient samples, including harmful IgG1 and IgM antibodies, ...

WELLESLEY HILLS, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, ...

Total Operating Expenses: Total operating expenses were $42.9 million for the first quarter of 2025, including research and ...

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T ™) products for cancer ...

Q1 2025 Earnings Conference Call May 9, 2025 10:00 AM ETCompany ParticipantsJustine Koenigsberg - Vice President ...